ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) — Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.
Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.
Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.
“Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.
Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.
Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
https://www.acuitivetech.com/
Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/233ecf43-c685-4d77-ba95-b1a49b14eecb
Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…
PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…
IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…
CHICAGO, Dec. 5, 2025 /PRNewswire/ -- Vaniam Group™, a category leader redefining medical communications, announced…
The Life Sciences BPO Market is expanding rapidly, driven by rising R&D costs, increasing regulatory…
Results confirm reproducibility and research readiness for islet isolation of Biorep's next generation laboratory platform.MIAMI,…